CA1108129A - Methode et appareil pour le traitement extravasculaire du sang - Google Patents

Methode et appareil pour le traitement extravasculaire du sang

Info

Publication number: CA1108129A
Authority: CA; Canada
Prior art keywords: blood; gel; sulfated polysaccharide; complex; agarose
Prior art date: 1978-06-09
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired

Application number

CA305,136A

Other languages

English (en)

Inventor

Paul J. Lupien

John A. Awad

Sital Moorjani

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Individual

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1978-06-09

Filing date

1978-06-09

Publication date

1981-09-01

1978-06-09 Application filed by Individual filed Critical Individual

1978-06-09 Priority to CA305,136A priority Critical patent/CA1108129A/fr

1981-09-01 Application granted granted Critical

1981-09-01 Publication of CA1108129A publication Critical patent/CA1108129A/fr

Status Expired legal-status Critical Current

Links

239000008280 blood Substances 0.000 title claims abstract description 121
210000004369 blood Anatomy 0.000 title claims abstract description 121
238000011282 treatment Methods 0.000 title claims abstract description 34
238000000034 method Methods 0.000 title claims description 38
150000004676 glycans Chemical class 0.000 claims abstract description 51
239000005017 polysaccharide Substances 0.000 claims abstract description 50
229920001282 polysaccharide Polymers 0.000 claims abstract description 45
229920000936 Agarose Polymers 0.000 claims description 29
ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 claims description 25
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 21
239000011575 calcium Substances 0.000 claims description 21
229910052791 calcium Inorganic materials 0.000 claims description 21
229920000669 heparin Polymers 0.000 claims description 20
HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical group NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 claims description 16
229960002897 heparin Drugs 0.000 claims description 13
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 12
150000001455 metallic ions Chemical class 0.000 claims description 12
-1 cyanogen halide Chemical class 0.000 claims description 10
239000000126 substance Substances 0.000 claims description 9
108010007622 LDL Lipoproteins Proteins 0.000 claims description 8
108010062497 VLDL Lipoproteins Proteins 0.000 claims description 8
JMANVNJQNLATNU-UHFFFAOYSA-N glycolonitrile Natural products N#CC#N JMANVNJQNLATNU-UHFFFAOYSA-N 0.000 claims description 8
230000008569 process Effects 0.000 claims description 8
239000002981 blocking agent Substances 0.000 claims description 6
229960000633 dextran sulfate Drugs 0.000 claims description 6
150000004804 polysaccharides Polymers 0.000 claims description 6
208000035150 Hypercholesterolemia Diseases 0.000 claims description 4
201000005577 familial hyperlipidemia Diseases 0.000 claims description 4
230000000903 blocking effect Effects 0.000 claims description 3
QPJDMGCKMHUXFD-UHFFFAOYSA-N cyanogen chloride Chemical compound ClC#N QPJDMGCKMHUXFD-UHFFFAOYSA-N 0.000 claims description 3
230000003213 activating effect Effects 0.000 claims description 2
230000009467 reduction Effects 0.000 claims description 2
238000004519 manufacturing process Methods 0.000 claims 1
102000004895 Lipoproteins Human genes 0.000 abstract description 30
108090001030 Lipoproteins Proteins 0.000 abstract description 30
238000001914 filtration Methods 0.000 abstract description 20
230000000260 hypercholesteremic effect Effects 0.000 abstract description 9
230000003516 hyperlipidaemic effect Effects 0.000 abstract description 7
150000004696 coordination complex Chemical class 0.000 abstract description 2
239000000499 gel Substances 0.000 description 116
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 46
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 21
235000012000 cholesterol Nutrition 0.000 description 15
239000011543 agarose gel Substances 0.000 description 14
239000000203 mixture Substances 0.000 description 14
239000011324 bead Substances 0.000 description 11
239000011780 sodium chloride Substances 0.000 description 11
BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 10
229910001424 calcium ion Inorganic materials 0.000 description 10
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
238000002360 preparation method Methods 0.000 description 8
ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 7
238000001802 infusion Methods 0.000 description 7
150000002632 lipids Chemical class 0.000 description 7
239000000047 product Substances 0.000 description 7
102000004169 proteins and genes Human genes 0.000 description 7
108090000623 proteins and genes Proteins 0.000 description 7
210000003462 vein Anatomy 0.000 description 7
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 6
229920002684 Sepharose Polymers 0.000 description 6
238000002474 experimental method Methods 0.000 description 6
239000012847 fine chemical Substances 0.000 description 6
229910052700 potassium Inorganic materials 0.000 description 6
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 5
230000008901 benefit Effects 0.000 description 5
238000006243 chemical reaction Methods 0.000 description 5
229910052708 sodium Inorganic materials 0.000 description 5
239000011734 sodium Substances 0.000 description 5
238000003756 stirring Methods 0.000 description 5
150000003626 triacylglycerols Chemical class 0.000 description 5
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
108010010234 HDL Lipoproteins Proteins 0.000 description 4
102000015779 HDL Lipoproteins Human genes 0.000 description 4
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
239000000872 buffer Substances 0.000 description 4
239000011521 glass Substances 0.000 description 4
239000008103 glucose Substances 0.000 description 4
150000003904 phospholipids Chemical class 0.000 description 4
239000011148 porous material Substances 0.000 description 4
210000002966 serum Anatomy 0.000 description 4
239000000243 solution Substances 0.000 description 4
102000009027 Albumins Human genes 0.000 description 3
108010088751 Albumins Proteins 0.000 description 3
229920002307 Dextran Polymers 0.000 description 3
230000004913 activation Effects 0.000 description 3
229960002086 dextran Drugs 0.000 description 3
201000010099 disease Diseases 0.000 description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
239000012153 distilled water Substances 0.000 description 3
229940079593 drug Drugs 0.000 description 3
239000003814 drug Substances 0.000 description 3
229960001008 heparin sodium Drugs 0.000 description 3
238000001556 precipitation Methods 0.000 description 3
239000006228 supernatant Substances 0.000 description 3
238000012360 testing method Methods 0.000 description 3
WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 description 2
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
108010082126 Alanine transaminase Proteins 0.000 description 2
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
102000006395 Globulins Human genes 0.000 description 2
108010044091 Globulins Proteins 0.000 description 2
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
229920004933 Terylene® Polymers 0.000 description 2
238000008050 Total Bilirubin Reagent Methods 0.000 description 2
PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 2
238000013019 agitation Methods 0.000 description 2
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
239000001110 calcium chloride Substances 0.000 description 2
229910001628 calcium chloride Inorganic materials 0.000 description 2
230000015271 coagulation Effects 0.000 description 2
238000005345 coagulation Methods 0.000 description 2
230000008878 coupling Effects 0.000 description 2
238000010168 coupling process Methods 0.000 description 2
238000005859 coupling reaction Methods 0.000 description 2
239000003792 electrolyte Substances 0.000 description 2
239000004744 fabric Substances 0.000 description 2
230000005484 gravity Effects 0.000 description 2
229940088597 hormone Drugs 0.000 description 2
239000005556 hormone Substances 0.000 description 2
JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
239000011777 magnesium Substances 0.000 description 2
229910052749 magnesium Inorganic materials 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
239000005020 polyethylene terephthalate Substances 0.000 description 2
239000011591 potassium Substances 0.000 description 2
239000002510 pyrogen Substances 0.000 description 2
238000009877 rendering Methods 0.000 description 2
235000017557 sodium bicarbonate Nutrition 0.000 description 2
229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
239000007787 solid Substances 0.000 description 2
239000011240 wet gel Substances 0.000 description 2
WZYRMLAWNVOIEX-MOJAZDJTSA-N (2s)-2-[(2r,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyacetaldehyde Chemical group O=C[C@@H](O)[C@@H]1OC[C@H](O)[C@H]1O WZYRMLAWNVOIEX-MOJAZDJTSA-N 0.000 description 1
ZACPHCCJSKOSJN-UHFFFAOYSA-M 1-[10-(4-amino-2-methylquinolin-1-ium-1-yl)decyl]-2-methylquinolin-1-ium-4-amine 1-hexadecylpyridin-1-ium triacetate Chemical compound CC([O-])=O.CC([O-])=O.CC([O-])=O.CCCCCCCCCCCCCCCC[n+]1ccccc1.Cc1cc(N)c2ccccc2[n+]1CCCCCCCCCC[n+]1c(C)cc(N)c2ccccc12 ZACPHCCJSKOSJN-UHFFFAOYSA-M 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
102100036475 Alanine aminotransferase 1 Human genes 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
101710088194 Dehydrogenase Proteins 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
235000010689 Lufa Nutrition 0.000 description 1
PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
108090000340 Transaminases Proteins 0.000 description 1
241000700605 Viruses Species 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
239000008272 agar Substances 0.000 description 1
239000003524 antilipemic agent Substances 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
230000017531 blood circulation Effects 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
239000002775 capsule Substances 0.000 description 1
150000001768 cations Chemical class 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
230000008859 change Effects 0.000 description 1
239000013043 chemical agent Substances 0.000 description 1
239000007795 chemical reaction product Substances 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 description 1
229960001214 clofibrate Drugs 0.000 description 1
229940000425 combination drug Drugs 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
230000037213 diet Effects 0.000 description 1
230000003292 diminished effect Effects 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
239000000835 fiber Substances 0.000 description 1
238000005227 gel permeation chromatography Methods 0.000 description 1
238000002523 gelfiltration Methods 0.000 description 1
230000009931 harmful effect Effects 0.000 description 1
231100001261 hazardous Toxicity 0.000 description 1
230000002489 hematologic effect Effects 0.000 description 1
229960000890 hydrocortisone Drugs 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
239000005457 ice water Substances 0.000 description 1
230000003993 interaction Effects 0.000 description 1
239000008101 lactose Substances 0.000 description 1
239000003912 lipotropic agent Substances 0.000 description 1
229940040504 lipotropic agent Drugs 0.000 description 1
239000007788 liquid Substances 0.000 description 1
238000003760 magnetic stirring Methods 0.000 description 1
229910052748 manganese Inorganic materials 0.000 description 1
239000011572 manganese Substances 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
208000007106 menorrhagia Diseases 0.000 description 1
239000011325 microbead Substances 0.000 description 1
102000039446 nucleic acids Human genes 0.000 description 1
108020004707 nucleic acids Proteins 0.000 description 1
150000007523 nucleic acids Chemical class 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
239000002245 particle Substances 0.000 description 1
239000002953 phosphate buffered saline Substances 0.000 description 1
238000000746 purification Methods 0.000 description 1
230000005855 radiation Effects 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
238000010517 secondary reaction Methods 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
102000014898 transaminase activity proteins Human genes 0.000 description 1
UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
238000009827 uniform distribution Methods 0.000 description 1
238000005406 washing Methods 0.000 description 1

Landscapes

Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

CA305,136A 1978-06-09 1978-06-09 Methode et appareil pour le traitement extravasculaire du sang Expired CA1108129A (fr)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
CA305,136A CA1108129A (fr)	1978-06-09	1978-06-09	Methode et appareil pour le traitement extravasculaire du sang

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
CA305,136A CA1108129A (fr)	1978-06-09	1978-06-09	Methode et appareil pour le traitement extravasculaire du sang

Publications (1)

Publication Number	Publication Date
CA1108129A true CA1108129A (fr)	1981-09-01

Family

ID=4111662

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA305,136A Expired CA1108129A (fr)	1978-06-09	1978-06-09	Methode et appareil pour le traitement extravasculaire du sang

Country Status (1)

Country	Link
CA (1)	CA1108129A (fr)

1978
- 1978-06-09 CA CA305,136A patent/CA1108129A/fr not_active Expired

Legal Events

Date	Code	Title	Description
1998-09-01	MKEX	Expiry

Publication	Publication Date	Title
US4103685A (en)	1978-08-01	Method and apparatus for extravascular treatment of blood
EP0237659B1 (fr)	1991-06-19	Procédé de préparation d'un immuno-adsorbant à base de protéine A-silice
AU621148B2 (en)	1992-03-05	Removal of process chemicals from labile biological mixtures by hydrophobic interaction chromatography
Eisenhauer et al.	1987	Selective removal of low density lipoproteins (LDL) by precipitation at low pH: first clinical application of the HELP system
EP0110409B1 (fr)	1989-04-19	Adsorbant et procédé pour le préparer
Cheung et al.	1986	Compartmental distribution of complement activation products in artificial kidneys
US4614513A (en)	1986-09-30	Method and apparatus for treatment to remove immunoreactive substances from blood
JPH08193031A (ja)	1996-07-30	水性液体からの腫瘍壊死因子αおよび細菌リポ多糖の同時除去方法
CA1086235A (fr)	1980-09-23	Systeme d'elimination continue de substances contenues dans le sang par circulation extracorporelle
Kikugawa et al.	1978	Filter columns for preparation of leukocyte-poor blood for transfusion
JPH105329A (ja)	1998-01-13	直接血液灌流に用いる吸着体用担体およびその小粒径化法
US4801449A (en)	1989-01-31	Method for treatment of Kaposi's sarcoma
WO1990004416A1 (fr)	1990-05-03	Extraction specifique de lipo-proteines de faible densite contenues dans le sang
WO1987007531A1 (fr)	1987-12-17	Elimination d'endotoxines
CA1108129A (fr)	1981-09-01	Methode et appareil pour le traitement extravasculaire du sang
Moorjani et al.	1977	Extracorporeal removal of plasma lipoproteins by affinity binding to heparin-agarose
CA1283073C (fr)	1991-04-16	Absorbant et procede pour la purification du facteur viii de coagulation du sang
Bernstein et al.	1987	Extracorporeal enzymatic heparin removal: Use in a sheep dialysis model
CA1222452A (fr)	1987-06-02	Pepsine immobilisee utilisee pour extraire des complexes immuns du sang et procede d'utilisation
CA1309020C (fr)	1992-10-20	Extraction extracorporelle de l'immunoglobuline-g et des complexes immuns circulants
Matsuda et al.	1996	Low–Density Lipoprotein Removal Methods by Membranes and Future Perspectives
US4565652A (en)	1986-01-21	Process for removing lipoproteins using derivatized polyhydroxymethylene
WO1989012390A1 (fr)	1989-12-28	Reactifs biocompatibles a reaction specifique selon les substances destines au traitement de fluides physiologiques
Smith et al.	1982	SORPTION–FILTRATION THERAPY FOR CHRONIC LIVER DISEASE: IN VITRO TESTING AND CLINICAL CORRELATION
Kadar et al.	1990	Biocompatibility of extracorporeal immunoadsorption systems